Connect with us

NEWS

EU legal action for vaccines lacks merit – AstraZeneca

Published

on

EU LEGAL action taken against AstraZeneca over shortfalls in its delivery of COVID-19 vaccines is without merit, the drugs giant said yesterday.

  In a statement after the European Commission launched proceedings against the drug manufacturing company, AstraZeneca said it had fully complied with the Advance Purchase Agreement with the European Commission.

  “We believe any litigation is without merit and we welcome this opportunity to resolve this dispute as soon as possible”.

  It added that in line with AstraZeneca’s forecast, the company is set to deliver almost 50 million doses to European nations by the end of April.

  “AstraZeneca regrets the European Commission’s decision to take legal action over the supply of COVID-19 vaccines,” the statement said.

  Continuing, “we look forward to working constructively with the EU Commission to vaccinate as many people as possible.”

  The EU executive and AstraZeneca have been at loggerheads as the British-Swedish company’s alleged shortfall of deliveries to the bloc hobbled the early efforts to roll out jabs.

  The commission, which has been responsible for procuring vaccines for all of the bloc, informed member states last week of its plans to take the company to court and pressed for support from national governments.

  Prime Minister Boris Johnson’s spokesman said he was unaware of the specifics around the legal action.

  “What I will say is that AstraZeneca has been a hugely strong partner for the UK and in fact, globally, for the work they’re doing,” he told reporters.

  “They’ve been a vital part of our vaccine rollout programme, and we continue to look forward to working with them.”

  Meanwhile, EU has commenced legal action against the company last Friday on the basis of breaches of the advanced purchase agreement,” EU spokesman Stefan De Keersmaecker disclosed.

  “Some terms of the contract have not been respected and the company has not been in a position to come up with a reliable strategy to ensure the timely delivery of doses.”

  De Keersmaecker said the action was launched by the EU executive on behalf of the 27 member states that are fully aligned in their support of this procedure.

  “What matters to us, in this case, is that we want to make sure that there’s a speedy delivery of a sufficient number of doses that European citizens are entitled to, and which have been promised on the basis of the contract,” he said.

  Following this development, the British-Swedish firm AstraZeneca dismissed the legal action as lacking in  merit,  insisting that doors are open for  resolution of the dispute as soon as possible.

  “AstraZeneca has fully complied with the Advance Purchase Agreement with the European Commission and will strongly defend itself in court,” it said in a statement.

  It will be recalled that the commission and company have been locked in a feud over a major shortfall in deliveries that hobbled early efforts in the bloc to roll out jabs.

  AstraZeneca said it was due to have delivered about 50 million doses to Europe by the end of April, but that is far lower than the amount Brussels insists should have come.

  The commission said the firm only provided 31 million of 120 million expected doses in the first three months of this year.

  The company has warned it will send just 70 million from another 180 million doses initially promised by June.

  AstraZeneca’s French-Australian boss Pascal Soriot has argued that his company’s contract with the EU binds it only to a best reasonable efforts clause.

  But the commission says the rest of the contract shows greater legal responsibility than that, and EU diplomats and lawmakers have pointed out that the company has largely delivered promised doses to Britain, where it is headquartered.

  Diplomats said any lawsuit against AstraZeneca would begin in a Belgian court — the jurisdiction agreed under the commission’s contract with the firm.

  The EU initially intended to use the AstraZeneca jab as the main workhouse to power the bloc’s inoculation drive but has now switched to the more expensive BioNTech/Pfizer vaccine as its mainstay.

  Pfizer is expected to deliver 250 million doses across the EU during the second quarter of this year as the 27 nations look to meet a target of vaccinating 70 per cent of adults by July.

  The bloc is hoping an uptick in deliveries — which also includes the Moderna and the single-shot Johnson & Johnson jabs — can help it gain ground on inoculation pacesetters like the United States and Britain.

  Public confidence in the AstraZeneca jab has also taken a blow over worries of links to very rare blood clots in the brain.

  Some member states have restricted use to older people despite the bloc’s medicines agency insisting the jab’s benefits outweigh the risks.

Continue Reading
Advertisement
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending